NCT05905965View on ClinicalTrials.gov

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Metabolic Syndrome
Interventions
DRUG

Empagliflozin 20 mg

Patients receiving empagliflozin 20 mg daily - experimental arm

DRUG

Empagliflozin 10 mg

Patients receiving empagliflozin 10 mg daily - control arm

Trial Locations (1)

85-094

RECRUITING

Cardiology Department, Dr. A. Jurasz University Hospital, Bydgoszcz

All Listed Sponsors
lead

Collegium Medicum w Bydgoszczy

OTHER